Search
Corbus Pharmaceuticals Holdings Inc
CRBPAdd to Watchlist
8.260USD
+0.210+2.61%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
146.52MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Corbus Pharmaceuticals Holdings Inc is 9.00, ranking 16 out of 389 in the Biotechnology & Medical Research industry. The average price target is 39.00, with a high of 53.00 and a low of 28.00.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
38.444
Target Price
+365.43%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Corbus Pharmaceuticals Holdings Inc
CRBP
10
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Corbus Pharmaceuticals Holdings Inc's price target?
Analysts forecast that Corbus Pharmaceuticals Holdings Inc's price target is USD 39.00, with the highest forecast at USD 53.00 and the lowest forecast at USD 28.00.
How have Corbus Pharmaceuticals Holdings IncCRBP's recent earnings per share performed?
The market expectation was USD -1.23, while Corbus Pharmaceuticals Holdings IncCRBP's earnings per share (EPS) for the previous quarter was USD -1.24. EPS for the next quarter is expected at USD -1.26.
What is the analyst rating for Corbus Pharmaceuticals Holdings Inc?
Based on the ratings of Corbus Pharmaceuticals Holdings Inc's stock from 10 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.
